Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases

Fig. 2

Comparison of PFS and OS between patients with and without brain metastases. (A), Comparison of PFS between patients with and without brain metastases in all included patients; (B), Comparison of PFS between patients with and without brain metastases in patients received ICI based monotherapy; (C), Comparison of PFS between patients with and without brain metastases in patients received ICI based combination therapy; (D), Comparison of OS between patients with and without brain metastases in all included patients; (E), Comparison of OS between patients with and without brain metastases in patients received ICI based monotherapy; (F), Comparison of OS between patients with and without brain metastases in patients received ICI based combination therapy. BrM, brain metastases

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us